-
Aug 8, 2024 | 
hcplive.com | Saakshi Khattri |Jennifer Soung |Kostas N. Botsoglou
August 8, 2024By Medical experts engage in a discussion surrounding the treatment and management of patients diagnosed with psoriasis and psoriatic arthritis.
-
Jul 29, 2024 | 
hcplive.com | Saakshi Khattri |Jennifer Soung |Kostas N. Botsoglou
July 29, 2024By Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management. Related Content Integrating Dry Eye Care Within Ophthalmic Surgery PracticeLaura Periman, MD;Kelly Nichols, OD;Alice Epitropoulos, MDJuly 1st 2024PodcastAddressing Suboptimal Anti-VEGF Response in Neovascular AMD and DMEHong-Uyen Hua, MD;Sruthi Arepalli, MD;Rishi P.
-
Jul 29, 2024 | 
consultantlive.com | Saakshi Khattri |Jennifer Soung |Kostas N. Botsoglou
Targeting Disease Modification in Psoriasis and Psoriatic ArthritisPublished on: July 29, 2024Dermatologic experts explore strategies to slow the progression of psoriasis to psoriatic arthritis, offering evidence-based insights to optimize patient outcomes and enhance long-term disease management.
-
Apr 26, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 26, 2024Experts conclude the series discussing how to approach switching psoriasis treatments. Dermatologists discuss their approach to managing patients who have experienced treatment failure. They debate whether to switch to a different class of drug or remain within the same class based on factors such as primary versus secondary failure and individual patient response.
-
Apr 26, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 26, 2024Experts discuss package warnings associated with bimekizumab and how they inform patients of them. Regarding the warnings in the bimekizumab package insert, specifically about suicidal ideation and elevated liver enzymes, different approaches are taken by physicians in discussing these potential side effects with patients, but each aim to address those concerns with their patients.
-
Apr 26, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 26, 2024Experts discuss bimekizumab for the treatment of psoriasis highlighting is efficacy over other treatments. Bimekizumab, a newly approved biologic for psoriasis, differs from existing biologics in that it blocks both IL-17A and IL-17F. This dual mechanism of action distinguishes it from previous IL-17 blockers, which targeted IL-17A alone.
-
Apr 19, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
April 19, 2024Experts discuss the warnings regarding IL-17 blockers and inflammatory bowel disease. In discussing the issue of inflammatory bowel disease (IBD) in patients receiving IL-17 blockers, the experts acknowledge the cautionary language in package inserts based on early studies. While there was initial concern about potential exacerbation of IBD with IL-17 blockers, subsequent real-world data have not shown increased or worsened IBD symptoms.
-
Apr 19, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
In patients with a positive test for tuberculosis (TB), the experts discuss their approach to treatment initiation with IL-17 and IL-23 blockers. They note that while TB monitoring remains a standard practice, the risk of TB reactivation with these biologics is low based on available evidence. Annual TB testing is not routinely recommended after treatment initiation due to the lack of signal for TB reactivation in meta-analyses of IL-17 and IL-23 blockers.
-
Apr 12, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
The experts discuss the management of psoriasis in patients with a history of cancer, emphasizing the favorable safety profile of IL-17 and IL-23 blockers compared to TNF inhibitors, which carry a boxed warning for cancer, particularly lymphoma. They note that patients with a history of cancer beyond five years or in remission can be safely considered for IL-17 and IL-23 blockers, and they advocate for collaboration with oncologists to ensure comprehensive care.
-
Apr 12, 2024 | 
hcplive.com | Mark Lebwohl |Saakshi Khattri |Mona Shahriari |Jennifer Soung
The focus shifts to the impact of comorbidities, particularly obesity and dyslipidemia, on the selection of psoriasis therapies. The dermatologists emphasize the importance of addressing obesity, noting its association with cardiovascular risks and metabolic syndrome. They discuss strategies for broaching the topic with patients, such as asking for permission to discuss weight loss and highlighting the potential benefits of weight loss medications in improving psoriasis severity.
